• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.

作者信息

Kenny Patrick R, Brady Daniel E, Torres Dawn M, Ragozzino Linda, Chalasani Naga, Harrison Stephen A

出版信息

Am J Gastroenterol. 2010 Dec;105(12):2707-9. doi: 10.1038/ajg.2010.363.

DOI:10.1038/ajg.2010.363
PMID:21131943
Abstract
摘要

相似文献

1
Exenatide in the treatment of diabetic patients with non-alcoholic steatohepatitis: a case series.艾塞那肽治疗非酒精性脂肪性肝炎糖尿病患者：病例系列
Am J Gastroenterol. 2010 Dec;105(12):2707-9. doi: 10.1038/ajg.2010.363.
2
Exenatide (Byetta) for type 2 diabetes.艾塞那肽（百泌达）用于2型糖尿病。
Med Lett Drugs Ther. 2005 Jun 6;47(1210):45-6.
3
Incretin mimetics as a novel therapeutic option for hepatic steatosis.肠促胰岛素类似物作为肝脂肪变性的一种新型治疗选择。
Liver Int. 2006 Oct;26(8):1015-7. doi: 10.1111/j.1478-3231.2006.01315.x.
4
Exenatide therapy in insulin-treated type 2 diabetes and obesity.利拉鲁肽治疗胰岛素治疗的 2 型糖尿病和肥胖症。
QJM. 2010 Sep;103(9):687-94. doi: 10.1093/qjmed/hcq112. Epub 2010 Jul 12.
5
Exenatide bid observational study (ExOS): baseline population characteristics of a prospective research study to evaluate the clinical effectiveness of exenatide bid use in patients with type 2 diabetes in a real-world setting.依西那肽双时相注射液观察性研究（ExOS）：一项前瞻性研究的基线人群特征，旨在评估依西那肽双时相注射液在真实世界环境中用于 2 型糖尿病患者的临床疗效。
Curr Med Res Opin. 2011 Mar;27(3):531-40. doi: 10.1185/03007995.2010.545814. Epub 2011 Jan 10.
6
Off-label use of exenatide for the management of insulin-resistant type 1 diabetes mellitus in an obese patient with human immunodeficiency virus infection.在一名患有人类免疫缺陷病毒感染的肥胖患者中，艾塞那肽用于治疗胰岛素抵抗型1型糖尿病的超说明书用药。
Pharmacotherapy. 2007 Oct;27(10):1449-55. doi: 10.1592/phco.27.10.1449.
7
Byetta update: what we've learned from experience.
Diabetes Self Manag. 2010 Mar-Apr;27(2):28, 30-1.
8
Extended-release exenatide (Bydureon) for type 2 diabetes.用于2型糖尿病的缓释艾塞那肽（百达扬）
Med Lett Drugs Ther. 2012 Mar 19;54(1386):21-3.
9
Challenges and strategies for moving patients to injectable medications.将患者转向注射用药物的挑战与策略。
Diabetes Educ. 2006 Mar-Apr;32 Suppl 2:82S-90S. doi: 10.1177/0145721706287653.
10
Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes.艾塞那肽长效释放制剂每周一次给药对2型糖尿病患者血糖控制和体重的影响。
Diabetes Care. 2007 Jun;30(6):1487-93. doi: 10.2337/dc06-2375. Epub 2007 Mar 12.

引用本文的文献

1
The Effect of Exenatide on Platelets Ratio Index and Fibrosis-4 Index in Obese Patients With Diabetes Mellitus.艾塞那肽对肥胖糖尿病患者血小板比率指数和纤维化-4指数的影响
Int J Endocrinol. 2025 Apr 28;2025:6332117. doi: 10.1155/ije/6332117. eCollection 2025.
2
NASH Drug Development: Seeing the Light at the End of the Tunnel?非酒精性脂肪性肝炎药物研发：曙光在前？
J Clin Transl Hepatol. 2023 Nov 28;11(6):1397-1403. doi: 10.14218/JCTH.2023.00058. Epub 2023 Jun 5.
3
Innovative Therapeutic Approaches in Non-Alcoholic Fatty Liver Disease: When Knowing Your Patient Is Key.
非酒精性脂肪性肝病的创新治疗方法：了解您的患者是关键。
Int J Mol Sci. 2023 Jun 27;24(13):10718. doi: 10.3390/ijms241310718.
4
GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives.GLP-1 受体激动剂在非酒精性脂肪性肝病中的应用：当前证据与未来展望。
Int J Mol Sci. 2023 Jan 15;24(2):1703. doi: 10.3390/ijms24021703.
5
Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways.代谢相关性脂肪性肝病（MAFLD）的分子机制：脂质代谢途径的功能分析。
Clin Sci (Lond). 2022 Sep 30;136(18):1347-1366. doi: 10.1042/CS20220572.
6
Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease.抗肥胖药物治疗非酒精性脂肪性肝病。
Curr Obes Rep. 2022 Sep;11(3):166-179. doi: 10.1007/s13679-022-00474-0. Epub 2022 May 2.
7
Screening Potential Drugs for the Development of NAFLD Based on Drug Perturbation Gene Set.基于药物扰动基因集筛选非酒精性脂肪性肝病（NAFLD）潜在药物。
Comput Math Methods Med. 2022 Apr 16;2022:7606716. doi: 10.1155/2022/7606716. eCollection 2022.
8
Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease.评估接受 exenatide 治疗的非酒精性脂肪性肝病糖尿病患者的肝纤维化、FIB-4 和 APRI 评分。
Sci Rep. 2022 Jan 7;12(1):283. doi: 10.1038/s41598-021-04361-x.
9
Brain-gut-liver interactions across the spectrum of insulin resistance in metabolic fatty liver disease.代谢性脂肪性肝病中胰岛素抵抗谱上的脑-肠-肝相互作用。
World J Gastroenterol. 2021 Aug 14;27(30):4999-5018. doi: 10.3748/wjg.v27.i30.4999.
10
Thiazolidinediones and Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Nonalcoholic Fatty Liver Disease: A Cohort Study.噻唑烷二酮类药物和胰高血糖素样肽-1 受体激动剂与非酒精性脂肪性肝病的风险：一项队列研究。
Hepatology. 2021 Nov;74(5):2467-2477. doi: 10.1002/hep.32012. Epub 2021 Aug 22.